HK

Hitesh Kumar

Active Director Director DIN 09540370
DIN 09540370 First appointment Apr 2022 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2022
Shareholding value •••• Premium profile

About Hitesh Kumar

Data last updated:

Hitesh Kumar is a Director at Sperlix Pharma Private Limited (since 2022). The company operates in Chemicals. Sperlix Pharma Private Limited reported revenue of ₹1.01 Cr (FY 2025).

DIN 09540370
Primary Designation Director
Industry Chemicals
First Appointment 18 Apr 2022
Oldest Company Age 4 yrs
Largest company Sperlix Pharma Private Limited · ₹1.01 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sperlix Pharma Private Limited U24230HR2022PTC102875
Director18 Apr 20222022₹1.01 Cr (FY 2025)Active

Board colleagues of Hitesh Kumar

NameDINCompanyDesignation
Prakash Chand09540416Sperlix Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Sperlix Pharma Private Limited
Premium access

Shareholding and investment profile for Hitesh Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hitesh Kumar

Hitesh Kumar currently holds 1 directorship: Sperlix Pharma Private Limited (Director, since 18 Apr 2022, revenue ₹1.01 Cr (FY 2025)).

Hitesh Kumar was first appointed on 18 Apr 2022 as Director at Sperlix Pharma Private Limited.

The current boards of Hitesh Kumar's companies include Prakash Chand (Sperlix Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available